A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2016
At a glance
- Drugs Cobimetinib (Primary) ; Dextromethorphan; Midazolam
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Genentech
- 16 Jul 2016 Results (n=97) published in the Investigational New Drugs
- 10 Jun 2016 Status changed from active, no longer recruiting to completed.
- 02 Jun 2015 Results assessing population pharmacokinetics from pooled data of MEK4592g, GO28141 and NO25395 trials presented at the 51st Annual Meeting of the American Society of Clinical Oncology.